Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On February 5, 2026, the Company held a Special Meeting of Stockholders (the "Special Meeting"). As of December 11, 2025, the record date for the Special Meeting, there were 2,693,531 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 1,196,312 shares were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Special Meeting. Each of these proposals is described in greater detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 2, 2026 (the "Proxy Statement").

Proposal 1. Approve the Nasdaq Proposal for Certain Warrants Issued on December 11, 2025 - The Company's stockholders approved the issuance of up to 2,610,823 shares of Company common stock upon the exercise of certain warrants issued on December 11, 2025, by the following vote:

Proposal 2. Approve an Amendment to Change the Company's Name from Moleculin Biotech, Inc. to Moleculin Inc. - The Company's stockholders did not approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to change the Company's name from Moleculin Biotech, Inc. to Moleculin Inc. (as such vote required a majority of the outstanding shares on the record date to vote "For" which did not occur) by the following vote:

Proposal 3. Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Proposal or the Name Change Proposal, by the following vote: